# Oral Cannabidiol for Opioid Withdrawal

> **NCT04238754** · PHASE1,PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 3 (actual)

## Conditions studied

- Opioid Withdrawal
- Opioid Craving
- Opioid Use Disorder

## Interventions

- **DRUG:** Epidiolex
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04238754
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238754, "Oral Cannabidiol for Opioid Withdrawal". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04238754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*